Search

Your search keyword '"Tomcikova D"' showing total 35 results
Start Over Author "Tomcikova D"
35 results on '"Tomcikova D"'

1. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Author

Dell’Aquila, E., Cremolini, C., Zeppola, T., Lonardi, S., Bergamo, F., Masi, G., Stellato, M., Marmorino, F., Schirripa, M., Urbano, F., Ronzoni, M., Tomasello, G., Zaniboni, A., Racca, P., Buonadonna, A., Allegrini, G., Fea, E., Di Donato, S., Chiara, S., Tonini, G., Tomcikova, D., Boni, L., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

2. PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study

Author

Marmorino, F., Cremolini, C., Loupakis, F., Antoniotti, C., Barbara, C., Dargenio, F., Miraglio, E., Masi, G., Salvatore, L., Schirripa, M., Borelli, B., Marcucci, L., Antonuzzo, L., Chiara, S., Banzi, C., Amoroso, D., Bonetti, A., Martignetti, A., Paris, M., Boni, L., Tomcikova, D., and Falcone, A.

Published
2016
Full Text
View/download PDF

3. O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO

Author

Antoniotti, C., Cremolini, C., Loupakis, F., Bergamo, F., Grande, R., Tonini, G., Garattini Silvio, K., Masi, G., Battaglin, F., Lucchesi, S., Salvatore, L., Corsi, D., Di Fabio, F., Banzi, M., Moretto, R., Sensi, E., Rossini, D., Tomcikova, D., Fontanini, G., Zagonel, V., Boni, L., and Falcone, A.

Published
2016
Full Text
View/download PDF

6. Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study

Author

Marmorino, F., primary, Cremolini, C., additional, Loupakis, F., additional, Salvatore, L., additional, Masi, G., additional, Barbara, C., additional, Dargenio, F., additional, Miraglio, E., additional, Ginocchi, L., additional, Antonuzzo, L., additional, Moretto, R., additional, Schirripa, M., additional, Chiara, S., additional, Banzi, C., additional, Amoroso, D., additional, Bonetti, A., additional, Martignetti, A., additional, Paris, M., additional, Boni, L., additional, Tomcikova, D., additional, and Falcone, A., additional

Published
2016
Full Text
View/download PDF

8. Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis

Author

Cremolini, C., primary, Loupakis, F., additional, Rossini, D., additional, Masi, G., additional, Salvatore, L., additional, Barbara, C., additional, Brunetti, I.M., additional, Antoniotti, C., additional, Granetto, C., additional, Cortesi, E., additional, Chiara, S., additional, Vitello, S., additional, Lonardi, S., additional, Ciuffreda, L., additional, Tomasello, G., additional, Ronzoni, M., additional, Buonadonna, A., additional, Tomcikova, D., additional, Boni, L., additional, and Falcone, A., additional

Published
2014
Full Text
View/download PDF

9. Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study

Author

Cremolini, C., primary, Loupakis, F., additional, Lonardi, S., additional, Tomasello, G., additional, Ronzoni, M., additional, Zaniboni, A., additional, Tonini, G., additional, Valsuani, C., additional, Chiara, S., additional, Boni, C., additional, Marcucci, L., additional, Negri, F.V., additional, Barone, C., additional, Vitello, S., additional, D'Amico, M., additional, Granetto, C., additional, Antoniotti, C., additional, Salvatore, L., additional, Fontanini, G., additional, Tomcikova, D., additional, Boni, L., additional, and Falcone, A., additional

Published
2014
Full Text
View/download PDF

11. D06 - Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study

Author

Marmorino, F., Cremolini, C., Loupakis, F., Salvatore, L., Masi, G., Barbara, C., Dargenio, F., Miraglio, E., Ginocchi, L., Antonuzzo, L., Moretto, R., Schirripa, M., Chiara, S., Banzi, C., Amoroso, D., Bonetti, A., Martignetti, A., Paris, M., Boni, L., Tomcikova, D., and Falcone, A.

Published
2016
Full Text
View/download PDF

12. F-41 Sorafenib for hepatocellular carcinoma (HCC) in patients with established cirrhosis: impact of the type of recruiting unit and predictors of survival

Author

Inghilesi, A., primary, Antonuzzo, L., additional, Gallori, D., additional, Forte, P., additional, Tomcikova, D., additional, Arena, U., additional, Colagrande, S., additional, Pradella, S., additional, Fani, B., additional, Gianni, E., additional, Boni, L., additional, Laffi, G., additional, Di Costanzo, F., additional, and Marra, F., additional

Published
2013
Full Text
View/download PDF

14. Abstracts

Author

Barthelemy, O., primary, Silvain, J., additional, Brieger, D., additional, Bellemain-Appaix, A., additional, Cayla, G., additional, Beygui, F., additional, Lancar, R., additional, Collet, J. P., additional, Mercadier, A., additional, Montalescot, G., additional, Cha, K. S., additional, Nam, Y. H., additional, Kim, J. H., additional, Park, S. Y., additional, Park, T. H., additional, Kim, M. H., additional, Kim, Y. D., additional, Lee, H. C., additional, Ahn, M. S., additional, Hong, T. J., additional, Blanco, R., additional, Blanco, F., additional, Szarfer, J., additional, Garcia Escudero, A., additional, Gigena, G., additional, Gagliardi, J., additional, Rodriguez, A., additional, Sarmiento, R., additional, Affatatto, S., additional, Riccitelli, M., additional, Petris, A., additional, Datcu, M. D., additional, Pop, C., additional, Radoi, M., additional, Arsenescu-Georgescu, C., additional, Petrescu, I., additional, Petrescu, L., additional, Serban, L., additional, Nechita, E., additional, Tatu-Chitoiu, G., additional, Dorobantu, M., additional, Benedek, I., additional, Craiu, E., additional, Sinescu, C., additional, Ionescu, D. D., additional, Ginghina, C., additional, Minescu, B., additional, Izzo, A., additional, Mantovani, P., additional, Tomasi, L., additional, Dall'oglio, L., additional, Bonatti, S., additional, Rosiello, R., additional, Romano, M., additional, Agostini, F., additional, Zanini, R., additional, Zhao, Z. Y., additional, Wu, Y. J., additional, Li, J. J., additional, Yany, Y. J., additional, Qian, H. Y., additional, Tang, Y. D., additional, Timoteo, A. T., additional, Toste, A., additional, Lousinha, A., additional, Ramos, R., additional, Oliveira, J. A., additional, Ferreira, M. L., additional, Ferreira, R. C., additional, Cabades, C., additional, Diez Gil, J. L., additional, Aguar, P., additional, Sanmiguel, D., additional, Lopez-March, A., additional, Marmol, R., additional, Guerra, L., additional, Girbes, V., additional, Ferrando, J., additional, Rincon De Arellano, A., additional, Patricio, L., additional, Blondal, M., additional, Ainla, T., additional, Marandi, T., additional, Eha, J., additional, Oliveira, M. M., additional, Silva, M. N., additional, Cunha, P. S., additional, Feliciano, J., additional, Silva, S., additional, Kanovsky, J., additional, Kala, P., additional, Parenica, J., additional, Poloczek, M., additional, Prymusova, K., additional, Kubkova, L., additional, Spinar, J., additional, Olinic, D., additional, Homorodean, C., additional, Ober, M., additional, Olinic, M., additional, Andrioaia, C., additional, Condac, A., additional, Masmoudi, M., additional, Berdaoui, B., additional, Labidi, S., additional, Tapia Ballesteros, C., additional, Hernandez Luis, C., additional, Sandin, M. G., additional, Vegas, J. M., additional, Andion, R., additional, Martinez, N., additional, Gonzalez, I. A., additional, Alvarado, M., additional, Amat, I. J., additional, San Roman, J. A., additional, Garcia Gonzalez, M. J., additional, Arroyo Ucar, E., additional, Hernandez Garcia, C., additional, Dorta Martin, M., additional, Marrero Rodriguez, F., additional, Dragu, R., additional, Kapeliovich, M., additional, Hammerman, H., additional, Silva, D., additional, Cortez-Dias, N., additional, Jorge, C., additional, Silva Marques, J., additional, Carilho Ferreira, P., additional, Robalo Martins, S., additional, Almeida Ribeiro, M., additional, Calisto, C., additional, Fiuza, M., additional, Lopes, M. G., additional, Milicevic, P., additional, Panic, M., additional, Stankovic, I., additional, Milicevic, D., additional, Kalezic, T., additional, Kafedzic, S., additional, Ilic, I., additional, Cerovic, M., additional, Putnikovic, B., additional, Neskovic, A., additional, Rott, D., additional, Leibowitz, D., additional, Monhart, Z., additional, Reissigova, J., additional, Grunfeldova, H., additional, Jansky, P., additional, Valente, B., additional, Villanueva Benito, I., additional, Solla, I., additional, Paredes, E., additional, Diaz Castro, O., additional, Calvo, F., additional, Baz, J. A., additional, Iniguez, A., additional, Aleksova, A., additional, Gerloni, R., additional, Belfiore, R., additional, Carriere, C., additional, Barbati, G., additional, Fabris, E., additional, Possa, F., additional, Nait, D., additional, Milo, M., additional, Sinagra, G., additional, Marques, N., additional, Mimoso, J., additional, Gomes, V., additional, Agra Bermejo, R. M., additional, Emad Abu Assi, E. A. A., additional, Sergio Raposeiras Roubin, S. R. R., additional, Pilar Cabanas Grandio, P. C. G., additional, Carlos Pena Gil, C. P. G., additional, Jose Maria Garcia Acuna, J. M. G. A., additional, Jose Ramon Gonzalez Juanatey, J. R. G. J., additional, Daly, M. J., additional, Scott, P., additional, Owens, C. G., additional, Tomlin, A., additional, Smith, B., additional, Adgey, A. A. J., additional, Alvarez-Contreras, L. R., additional, Juarez, U., additional, Altamirano, A., additional, Arias, A., additional, Alvarez-San Gabriel, A., additional, Gonzalez-Pacheco, H., additional, Martinez-Sanchez, C., additional, Rahnavardi, M., additional, Keshtkar-Jahromi, M., additional, Vakili, H., additional, Gholamin, S., additional, Razavi, S. M., additional, Gilis-Januszewski, T., additional, Mellwig, K.- P., additional, Wiemer, M., additional, Gilis-Januszewski, J., additional, Peterschroeder, A., additional, Koerfer, J., additional, Horstkotte, D., additional, Vrsalovic, M., additional, Getaldic, B., additional, Vrkic, N., additional, Pintaric, H., additional, Khan, S., additional, Wasan, B., additional, Moretti, L., additional, Grossi, P., additional, Silenzi, S., additional, Testa, M., additional, Candelori, L., additional, Clementi, L. N., additional, Forlini, M., additional, Lando, L., additional, Pezzuoli, M. L., additional, Corradetti, P., additional, Leurent, G., additional, Pennec, P. Y., additional, Filippi, E., additional, Moquet, B., additional, Hacot, J. P., additional, Druelles, P., additional, Rialan, A., additional, Rouault, G., additional, Coudert, I., additional, Le Breton, H., additional, Gevaert, S., additional, Tromp, F., additional, Vandecasteele, E., additional, De Somer, F., additional, Van Belleghem, Y., additional, Bouchez, S., additional, Martens, F., additional, Herck, I., additional, De Pauw, M., additional, Ludka, O., additional, Sepsi, M., additional, Miklik, R., additional, Dusek, L., additional, Tomcikova, D., additional, Garcia-Acuna, J. M., additional, Aguiar-Souto, P., additional, Raposeiras Roubin, S., additional, Agra-Bermejo, R., additional, Jacquet, M., additional, Abu-Assi, E., additional, Gonzalez-Juanatey, J. R., additional, Ibatov, A., additional, Labrova, R., additional, Karlik, R., additional, Lokaj, P., additional, She, Q., additional, Deng, S. B., additional, Huang, S. H., additional, Gu, L. J., additional, Rong, J. I. A. N., additional, Wu, Z. K., additional, Li, Y., additional, Zhang, J., additional, Parascan, L., additional, Campanile, A., additional, Spinelli, L., additional, Santulli, G., additional, Ciccarelli, M., additional, De Gennaro, S., additional, Assante Di Panzillo, E., additional, Trimarco, B., additional, Iaccarino, G., additional, Bobescu, E., additional, Datcu, G., additional, Dobreanu, D., additional, Doka, B., additional, Charniot, J.- C., additional, Cosson, C., additional, Albertini, J. P., additional, Bittar, R., additional, Giral, P., additional, Cherfils, C., additional, Guillerm, E., additional, Bonnefont-Rousselot, D., additional, Rusali, A., additional, Cojocaru, L., additional, Parepa, I., additional, Koizumi, T., additional, Iida, S., additional, Sato, J., additional, Kikutani, T., additional, Muramatsu, T., additional, Nishimura, S., additional, Komiyama, N., additional, Lee, W. P., additional, Ong, B. B., additional, Haralambos, K., additional, Townsend, D., additional, Rees, J. A. E., additional, Williams, E. J., additional, Halcox, J. P., additional, Mcdowell, I., additional, Damjanovic, M., additional, Koracevic, G., additional, Djordjevic-Radojkovic, D., additional, Pavlovic, M., additional, Krstic, N., additional, Ciric-Zdravkovic, S., additional, Stojkovic, A., additional, Perisic, Z., additional, Apostolovic, S., additional, Faustino, A., additional, Seca, L., additional, Barra, S., additional, Caetano, F., additional, Providencia, R., additional, Silva, J., additional, Gomes, P., additional, Costa, G., additional, Costa, M., additional, Leitao-Marques, A., additional, Volkova, A. L., additional, Arutyunov, G. P., additional, Bylova, N. A., additional, Dayter, I. I., additional, Jao, Y. T. F. N., additional, Fang, C. C., additional, Chen, Y., additional, Yu, C. L., additional, Wang, S. P., additional, Valencia, J., additional, Perez-Berbel, P., additional, Ruiz-Nodar, J. M., additional, Pineda, J., additional, Bordes, P., additional, Quintanilla, M., additional, Mainar, V., additional, Sogorb, F., additional, Santos, N., additional, Serrao, M., additional, Cafe, H., additional, Silva, B., additional, Oliveira, R., additional, Caires, G., additional, Drumond, A., additional, Araujo, J., additional, Providencia, R. A., additional, Gomes, P. L., additional, Pais, J. R., additional, Mota, P., additional, Leitao-Marques, A. M., additional, Farhan, S., additional, Jarai, R., additional, Tentzeris, I., additional, Vogel, B., additional, Freynhofer, M. K., additional, Wojta, J., additional, Huber, K., additional, Poli, M., additional, Trambaiolo, P., additional, Corsi, F., additional, De Luca, M., additional, Mustilli, M., additional, Lukic, V., additional, Simonetti, M., additional, Ferraiuolo, G., additional, Lettino, M., additional, Casella, G., additional, Conte, M. R., additional, De Luca, L., additional, Geraci, G., additional, Ceravolo, R., additional, Pani, A., additional, Fradella, G., additional, Schratter, A., additional, Thiele, H., additional, Klemm, T., additional, Demmin, K., additional, Lehmann, D., additional, Mende, M., additional, Schuler, G., additional, Pittl, U., additional, Chernova, A., additional, Nikulina, S. U., additional, Naruke, T., additional, Inomata, T., additional, Yanagisawa, T., additional, Maekawa, E., additional, Mizutani, T., additional, Shinagawa, H., additional, Nishii, M., additional, Takeuchi, I., additional, Takehana, H., additional, Izumi, T., additional, Paulo, C., additional, Mascarenhas, J., additional, Patacho, M., additional, Pimenta, J., additional, Bettencourt, P., additional, Nardai, S., additional, Szabo, G. Y., additional, Berta, B., additional, Edes, I., additional, Merkely, B., additional, Delgado Silva, J., additional, Baptista, R., additional, Faria, R., additional, Trigo, J., additional, Gago, P., additional, Gheorghe, G., additional, Nanea, I. T., additional, Cristea, A., additional, Almarichi, S., additional, Martins, H., additional, Saraiva, F., additional, Jorge, E., additional, Mendes, P. L., additional, Monteiro, P., additional, Costa, S., additional, Franco, F., additional, Providencia, L. A., additional, Nanea, T., additional, Gheorghe, G. S., additional, Visan, S., additional, Paun, N., additional, Gaber, R., additional, Delewi, R., additional, Nijveldt, R., additional, De Bruin, H. A., additional, Hirsch, A., additional, Van Der Laan, A., additional, Bouma, B. J., additional, Tijssen, J. P. G., additional, Van Rossum, A. C., additional, Zijlstra, F., additional, Piek, J. J., additional, Rus, H., additional, Donea, M., additional, Ciurea, C., additional, Ifteni, G., additional, Casolo, G., additional, Chioccioli, M., additional, Magnacca, M., additional, Del Meglio, J., additional, Comella, A., additional, Baratto, M., additional, Lera, J., additional, Salvadori, L., additional, Tessa, C., additional, Vignali, C., additional, Keca, Z., additional, Momcilov Popin, T., additional, Panic, G., additional, White, R., additional, Mateen, F., additional, Weaver, A., additional, Agmon, Y., additional, Okisheva, E., additional, Tsaregorodtsev, D., additional, Sulimov, V., additional, Amat Santos, I. J., additional, Hernandez, C., additional, Tapia, C., additional, Campo, A., additional, Fredman, D., additional, Svensson, L., additional, Rosenqvist, M., additional, Tadel-Kocjancic, S., additional, Radsel, P., additional, Knafelj, R., additional, Gorjup, V., additional, Noc, M., additional, Zima, E., additional, Jenei, Z. S., additional, Kovacs, E., additional, Osztheimer, I., additional, Molnar, L., additional, Horvath, A., additional, Becker, D., additional, Geller, L., additional, Maggi, R., additional, Furukawa, T., additional, Viscardi, V., additional, Brignole, M., additional, Leal, S. R. N., additional, Dores, H., additional, Rosario, I., additional, Monge, J., additional, Carvalho, M. J., additional, Arroja, I., additional, Leitao, A., additional, Fonseca, C., additional, Aleixo, A., additional, Silva, A., additional, Keuleers, S., additional, Herijgers, P., additional, Herregods, M. C., additional, Budts, W., additional, Dubois, C., additional, Meuris, B., additional, Verhamme, P., additional, Flameng, W., additional, Van De Werf, F., additional, Adriaenssens, T., additional, Badran, H., additional, Elnoamany, M., additional, Lolah, T., additional, Olariu, C., additional, Macarie, C., additional, Mollik, M. A. H., additional, Hassan, A. I., additional, Paul, T. K., additional, Haque, M. Z., additional, Jahan, R., additional, Rahmatullah, M., additional, Khatun, M. A., additional, Rahman, M. T., additional, Chowdhury, M. H., additional, Bustamante Munguira, J., additional, Tamayo, E., additional, Garcia-Cuenca, I., additional, Bustamante, E., additional, Gualis, J., additional, Gomez-Martinez, M. L., additional, Florez, S., additional, Gomez-Herreras, J. I., additional, Ramirez Rodriguez, R., additional, Ramirez Rodriguez, A. M., additional, Garcia-Bello, M. A., additional, Hernadez Ortega, E., additional, Caballero Dorta, E., additional, Garcia Quintana, A., additional, Piro Mastraccio, V., additional, Medina Fernandez Aceytuno, A., additional, Assanelli, E., additional, De Metrio, M., additional, Rubino, M., additional, Lauri, G., additional, Cabiati, A., additional, Campodonico, J., additional, Grazi, M., additional, Moltrasio, M., additional, Marana, I., additional, Marenzi, G., additional, Lovlien, M., additional, Schei, B., additional, Picon-Heras, R., additional, Acebal, C., additional, Garcia Rubira, J. C., additional, Vivas Balcones, D., additional, Nunez-Gil, I., additional, Ruiz-Mateos, B., additional, Ibanez, B., additional, Fernandez-Ortiz, A., additional, Vintila, V. D., additional, Enescu, O. A., additional, Stoicescu, C. I., additional, Udroiu, C., additional, Cinteza, M., additional, Tatu - Chitoiu, G., additional, Vinereanu, D., additional, Fresco, C., additional, De Biasio, M., additional, Muser, D., additional, Sappa, R., additional, Morocutti, G., additional, Bernardi, G., additional, Proclemer, A., additional, Fontanella, B., additional, Affatato, A., additional, Ciccarese, C., additional, Sacchini, M., additional, Volpini, M., additional, Bianchetti, F., additional, Verzura, G., additional, Dei Cas, L., additional, Pudil, R., additional, Blaha, V., additional, Vojacek, J., additional, Paraskevaidis, I., additional, Ikonomidis, I., additional, Parissis, J., additional, Papadopoulos, C., additional, Stasinos, V., additional, Bistola, V., additional, Anastasiou-Nana, M., additional, Shochat, M., additional, Shotan, A., additional, Kazatsker, M., additional, Gurovich, V., additional, Asif, A., additional, Noiman, E., additional, Levy, Y., additional, Blondhaim, D., additional, Rabinovich, P., additional, Meisel, S., additional, Petrovic, S., additional, Glasnovic, J., additional, Tomasevic, M., additional, Sakac, D., additional, Obradovic, S., additional, Londono Sanchez, O., additional, Pacreu, S., additional, Torres, L., additional, Mihaylov, G., additional, Shaban, G. M., additional, Trendafilova, E., additional, Krasteva, V., additional, Mudrov, T. S., additional, Didon, J. P., additional, Panageas, V., additional, Vlachos, N., additional, Pernat, A., additional, Radan, I., additional, Mozina, H., additional, Pepi, P., additional, Cionini, F., additional, Baccaglioni, N., additional, Viertel, A., additional, Havers, J., additional, Ballard, G., additional, Groenefeld, G., additional, Branco, L. M., additional, Ferreira, L., additional, Fiarresga, A., additional, Lettieri, L., additional, Reggiani, A., additional, Juarez Prera, R., additional, Blanco Palacios, G., additional, Martin, A.- C., additional, Manzo Silberman, S., additional, Chaib, A., additional, Varenne, O., additional, Allouch, P., additional, Salengro, E., additional, Jegou, A., additional, Margot, O., additional, Spaulding, C., additional, Diego, A., additional, De Miguel, A., additional, Cuellas, C., additional, Fraile, E., additional, Martin, J., additional, Vega, B., additional, Bangueses, R., additional, Fernandez-Vazquez, F., additional, Perez De Prado, A., additional, Leal, S., additional, Correia, M. J., additional, Monge, J. C., additional, Abecasis, J., additional, Garcia-Garcia, C., additional, Subirana, I., additional, Sala, J., additional, Bruguera, J., additional, Valle, V., additional, Sanz, G., additional, Fiol, M., additional, Aros, F., additional, Marrugat, J., additional, Elosua, R., additional, Barra, S. N. C., additional, Leitao Marques, A., additional, Yang, Y. J., additional, Xu, B., additional, Song, G. Y., additional, G, R. L., additional, Aleksic, A., additional, Serpytis, P., additional, Rucinskas, K., additional, Kalinauskas, A., additional, Karvelyte, N., additional, Santos De Sousa, C. I., additional, Ferreira, S., additional, Calaca, J., additional, Lousada, N., additional, Palma Reis, R., additional, Gualandro, D. M., additional, Seguro, L. F. B. C., additional, Braga, F. G. M., additional, Silvestre, O. M., additional, Lage, R. L., additional, Fabri, J., additional, Oliveira, M. T., additional, Urbano Moral, J. A., additional, Torres Llergo, J., additional, Solanilla Rodriguez, R., additional, Sanchez Gonzalez, A., additional, Martinez Martinez, A., additional, Den Uil, C. A., additional, Lagrand, W. K., additional, Van Der Ent, M., additional, Jewbali, L. S. D., additional, Cheng, J. M., additional, Spronk, P. E., additional, Simoons, M. L., additional, Mornos, C., additional, Dragulescu, D., additional, Ionac, A., additional, Guardado, J., additional, Azevedo, O., additional, Fernandes, M., additional, Canario-Almeida, F., additional, Sanfins, V., additional, Pereira, A., additional, Almeida, J., additional, Kaplunova, V. U., additional, Belenkov, Y. N., additional, Privalova, E. V., additional, Fomin, A. A., additional, Suvorov, A. Y., additional, Goodkova, A., additional, Rubakova, M. G., additional, Kuznetsova, I. A., additional, Semernin, E. N., additional, Keshavarzi, F., additional, Kojuri, J., additional, Mikhailov, V. M., additional, Vezhenkova, I. V., additional, Goodkova, A. Y. A., additional, Pavlovic, I., additional, Schwarz, M., additional, Jakl, G., additional, Smetana, P., additional, Perkmann, T., additional, Mayr, A., additional, Mair, J., additional, Klug, G., additional, Schocke, M., additional, Trieb, T., additional, Jaschke, W., additional, Pachinger, O., additional, Metzler, B., additional, Bronze Carvalho, L., additional, Azevedo, J., additional, Andrade, M. L., additional, Relvas, M. J., additional, Coucello, J., additional, Morais, G., additional, Seabra, M., additional, Afamefule, F., additional, Luaces Mendez, M., additional, Teijeiro-Mestre, R., additional, Nunez-Gil, I. J., additional, Leco-Gil, N., additional, Madronal-Cerezo, E., additional, Zannin, I., additional, Ruiz, J., additional, Orynchak, M. A., additional, Vakalyuk, I. I., additional, Vakalyuk, I. P., additional, Berezin, A., additional, Panasenko, T., additional, Cavusoglu, Y., additional, Cavusoglu, A., additional, Unluoglu, I., additional, Tek, M., additional, Demirustu, C., additional, Gorenek, B., additional, Unalacak, M., additional, Birdane, A., additional, Yuksel, F., additional, Ata, N., additional, Halcox, J. P. J., additional, Beyaztas, A., additional, Entok, E., additional, Uslu, I., additional, Schaefer, A., additional, Flierl, U., additional, Seydelmann, N., additional, Bauersachs, J., additional, Calmac, L., additional, Marinescu, S., additional, Tatu Chitoiu, G., additional, Fruntelata, A. G., additional, Hamdi, S., additional, Maazoun, Y., additional, Neji, A., additional, Farhat, O., additional, Majdoub, M., additional, Ben Hamda, K., additional, Maatouk, F., additional, Balanescu, S. M., additional, Nedelciuc, I., additional, Deleanu, D., additional, Ortan, F., additional, Mot, S., additional, Sinnaeve, P. R., additional, Moreels, S., additional, Coosemans, M., additional, Vydt, T., additional, Desmet, W., additional, Tobing, D., additional, Rifnaldi, R., additional, Juzar, D., additional, Firdaus, I., additional, Dharma, S., additional, Irmalita, I., additional, Kalim, H., additional, Bejiqi, R., additional, Retkoceri, R., additional, Bejiqi, H., additional, Kryeziu, L., additional, Kelmendi, M., additional, Borovci, S. H., additional, Victor, S. M., additional, Gnanaraj, A., additional, Deshmukh, R., additional, Mullasari, A. S., additional, Yahalom, M., additional, Kaiyal, R. S., additional, Roguin, N., additional, Bornstein, J., additional, Atar, S., additional, Farah, R., additional, Seca, L. F., additional, Leitao Marques, A. M., additional, Margato, R., additional, Sousa, P., additional, Ribeiro, H., additional, Rocha, L., additional, Correia, A., additional, Moreira, J. I., additional, Carvalho, H. C., additional, Afifi, M., additional, Abed, N., additional, Suarez-Barrientos, A., additional, Vivas, D., additional, Castro-Ferreira, F., additional, Franco, E., additional, Garcia-Rubira, J. C., additional, Fuster, V., additional, Macaya, C., additional, Ibanez Cabeza, B., additional, Salinger, S., additional, Milic, D., additional, Stanojlovic, T., additional, Kostic, T., additional, Khan, M. A., additional, Vrapi, F., additional, Naeem, K., additional, Davar, J., additional, Hristova, K., additional, Pencheva, G., additional, Radeva, R., additional, Milanov, S., additional, Fareed, A., additional, Oraby, M., additional, Nasr, G. M., additional, Maklady, F., additional, Dupouy, P., additional, Sorensen, J. T., additional, Terkelsen, C. J., additional, Lassen, J. F., additional, Trautner, S., additional, Christensen, E. F., additional, Nielsen, T. T., additional, Botker, H. E., additional, Andersen, H. R., additional, Thygesen, K. A., additional, Checco, L., additional, Usmiani, T., additional, Sbarra, P. L., additional, Boffini, M., additional, Saviolo, R., additional, Grasso, C., additional, Conrotto, F., additional, Marchetti, M., additional, Rinaldi, M., additional, Marra, S., additional, Moscoso Costa, F., additional, Ferreira, J., additional, Raposo, L., additional, Aguiar, C., additional, Trabulo, M., additional, Silva, J. A., additional, Marques, V., additional, Swiatkowski, A., additional, Kowalczyk, J., additional, Lenarczyk, R., additional, Chodor, P., additional, Honisz, G., additional, Was, T., additional, Swierad, M., additional, Sredniawa, B., additional, Polonski, L., additional, Kalarus, Z., additional, Postadzhiyan, A. S., additional, Velinov, H., additional, Velchev, V., additional, Hazarbasanov, D., additional, Apostolova, M., additional, Finkov, B., additional, Petrovic, M., additional, Jovelic, A., additional, Canji, T., additional, Srdanovic, I., additional, Popov, T., additional, Golubovic, M., additional, Pavlovic, K., additional, Cemerlic-Adjic, N., additional, Bro-Jeppesen, J., additional, Kjaergaard, J., additional, Wanscher, M. C., additional, Nielsen, S. L., additional, Rasmussen, L. S., additional, Hassager, C., additional, Khan, M., additional, Crolla, E., additional, Morley, H., additional, Akeroyd, L., additional, Beaini, Y., additional, Morley, C., additional, Bekeredjian, R. H., additional, Krumsdorf, U., additional, Rottbauer, W., additional, Katus, H. A., additional, Pleger, S., additional, Botelho, A., additional, Quintal, N., additional, Faria, P., additional, Gomes, S., additional, Roussel, J. C., additional, Senage, T., additional, Perigaud, C., additional, Habash, O., additional, Michel, M., additional, Treilhaud, M., additional, Despins, P., additional, Trochu, J. N., additional, Baron, O., additional, Duveau, D., additional, Kitsiou, A. N., additional, Giannakopoulos, K., additional, Papadimitriou, G., additional, Karas, S., additional, Babic, Z., additional, Nikolic Heitzler, V., additional, Milicic, D., additional, Bergovec, M., additional, Raguz, M., additional, Mirat, J., additional, Strozzi, M., additional, Plazonic, Z., additional, Giunio, L., additional, Steiner, R., additional, Freynhofer, M., additional, Brozovic, I., additional, Bruno, V., additional, Leherbauer, L., additional, Djurkovic, M., additional, Willheim, M., additional, Huebl, W., additional, Hahne, S., additional, Kozanli, I., additional, Kalla, K., additional, Geppert, A., additional, Unger, G., additional, Simoes Marques Assuncao Caetano, A. F., additional, Faustino, C., additional, Ariza Sole, A., additional, Sanchez Salado, J. C., additional, Lorente Tordera, V., additional, Martinez Garcia, V., additional, Salazar Mendiguchia Y Garcia, J., additional, Gomez Hospital, J. A., additional, Maristany Daunert, J., additional, Berdejo Gago, F. J., additional, Esplugas Oliveras, E., additional, Brzozowska-Czarnek, A., additional, Urbanik, A., additional, Kakouros, N., additional, Kakouros, S., additional, Lekakis, J., additional, Rizos, J., additional, Kokkinos, D., additional, Venevtseva, J., additional, Melnikov, A., additional, Valiahmetov, M., additional, Gomova, T., additional, Perelomova, I., additional, Ferrer Hita, J. J., additional, Bosa-Ojeda, F., additional, Sanchez-Grande-Flecha, A., additional, Yanes-Bowden, G., additional, Vargas-Torres, M. J., additional, Rodriguez-Gonzalez, A., additional, Rubio-Iglesias-Garcia, C., additional, Dominguez-Rodriguez, A., additional, Enjuanes-Grau, C., additional, Marrero-Rodriguez, F., additional, Suceveanu, A. I., additional, Suceveanu, A., additional, Mazilu, L., additional, Alexandrescu, L., additional, Dumitru, E., additional, Miu, V., additional, Jitari, V., additional, Voinea, F. L., additional, Balachandran, K. P., additional, Schofield, R., additional, Sankaranarayanan, R., additional, Helm, K., additional, Crowe, C., additional, Singh, R., additional, Mcdonald, J., additional, Chuen, M. J., additional, Kobusiak-Prokopowicz, M., additional, Preglowska, M., additional, Mysiak, A., additional, Doi, T., additional, Sakoda, T., additional, Akagami, T., additional, Naka, T., additional, Tsujino, T., additional, Masuyama, T., additional, Ohyanagi, M., additional, Kume, N., additional, Mitsuoka, H., additional, Hayashida, K., additional, Tanaka, M., additional, Biasucci, L. M., additional, Della Bona, R., additional, Biasillo, G., additional, Leo, M., additional, Zaninotto, M., additional, Plebani, M., additional, Crea, F., additional, Dellabona, R., additional, Gok, B., additional, Unalir, A., additional, Timuralp, B., additional, Nikulina, N., additional, Yakushin, S. S., additional, Furmenko, G. I., additional, Akinina, S. A., additional, Ingrid, R., additional, Bronze, L., additional, Djambazov, S., additional, Zhivkov, A., additional, Maznev, I., additional, Ingeliev, M., additional, Slavov, R., additional, Cvetkova, N., additional, Patarinski, V., additional, Groch, L., additional, Horak, J., additional, Dimitrov, N., additional, Hayrapetyan, H. G., additional, Cabanas-Grandio, P., additional, Pena-Gil, C., additional, Mc Keag, N. A., additional, Mc Cann, C. J., additional, Cardwell, C., additional, Young, I. S., additional, Mikhalchikova, N., additional, Burova, N., additional, Zaccaria, M., additional, Palmisano, P., additional, Palumbo, V., additional, Ciccone, M. M., additional, Favale, S., additional, Chen, K. C., additional, Yin, W. H., additional, Liu, J. H., additional, Goncalves, S., additional, Santos, J. F., additional, Amador, P., additional, Soares, L. N., additional, Zahidova, K., additional, Guliyev, F., additional, Zahidov, N., additional, Carrilho-Ferreira, P., additional, Marques, J. S., additional, Carvalho De Sousa, J., additional, Uthoff, H., additional, Thalhammer, C., additional, Potocki, M., additional, Reichlin, T., additional, Noveanu, M., additional, Aschwanden, M., additional, Staub, D., additional, Arenja, N., additional, Socrates, T., additional, Mueller, C., additional, Zhao, Y., additional, Wu, X., additional, Xue, Q., additional, Gao, L., additional, Lin, H., additional, Wang, S., additional, Watanabe, K., additional, Kawamura, A., additional, Seko, T., additional, Omura, A., additional, Sakabe, S., additional, Kasai, A., additional, Starodubova, A. V., additional, Storozhakov, G., additional, Kisliak, O., additional, Hautieva, F., additional, Tursheva, M., additional, Fedotova, N., additional, Di Maio, R. C., additional, Mclaughlin, J., additional, Allen, J. D., additional, Anderson, J. M. C., additional, Khaled Nagi, H., additional, Tayeh, O., additional, Farok, W., additional, Mousa, A., additional, Neuzil, P., additional, Skoda, J., additional, Petru, J., additional, Sediva, L., additional, Kralovec, S., additional, Holy, F., additional, Holdova, K., additional, Jehlicka, P., additional, Plasil, P., additional, Reddy, V. Y., additional, Alabakovska, S., additional, Labudovic, D., additional, Jovanova, S., additional, Tosheska, K., additional, Alabakovski, M., additional, Jeevaratnam, K., additional, Tee, S. P., additional, Zhang, Y., additional, Guzadhur, L., additional, Gurung, I. S., additional, Duehmke, R., additional, Grace, A. A., additional, Lei, M., additional, Huang, C. L., additional, Ishibashi, Y., additional, Yamauchi, M., additional, Akashi, Y., additional, Musha, H., additional, Miyake, F., additional, Hnatek, T., additional, Kamenik, L., additional, Sedlon, P., additional, Luxova, J., additional, Steuerova, B., additional, Skvaril, J., additional, Cernohous, M., additional, Zavoral, M., additional, Ratkovic, N., additional, Nemanja Djenic, N. R., additional, Aleksandra Jovelic, A. J., additional, Slobodan Obradovic, S. O., additional, Branko Gligic, B. G., additional, Kletsiou, E., additional, Giannakopoulou, M., additional, Bozas, E., additional, Iliodromitis, E. K., additional, Papathanassoglou, E. D. E., additional, Anton, M., additional, Anton, G., additional, Muraru, M., additional, Salinger Martinovic, S., additional, Radosavljevic, M., additional, Stanojevic, D., additional, Zivkovic, M., additional, Pessoa, T., additional, Aspromonte, N., additional, Ronco, C., additional, Tubaro, M., additional, Santini, M., additional, Colivicchi, F., additional, Aiello, A., additional, Cruz, D., additional, Anzoletti Boscolo, A., additional, Vianello, G., additional, Valle, R., additional, Parspour, A., additional, Watkins, S., additional, Datta, D., additional, Nikishin, A. G., additional, Pirnazarov, M. M., additional, Nurbaev, T. A., additional, Motovska, Z., additional, Fischerova, M., additional, Osmancik, P., additional, Maly, M., additional, Widimsky, P., additional, Pavli, E., additional, Dibra, A., additional, Mehilli, J., additional, Dibra, L., additional, Schoemig, A., additional, Kastrati, A., additional, Carmo, P., additional, Almeida, M., additional, Teles, R., additional, Goncalves, P., additional, Brito, J., additional, D'ascenzo, F., additional, Gonella, A., additional, Longo, G., additional, Pullara, A., additional, Moretti, C., additional, Sciuto, F., additional, Omede', P., additional, Biondi Zoccai, G., additional, Trevi, G. P., additional, Sheiban, I., additional, Cafe, H. M., additional, Pereira, D., additional, Freitas, D., additional, Ortiz Berbel, D., additional, Rabasa Baraibar, J. M., additional, Leone, A. M., additional, De Caterina, A., additional, Aurelio, A., additional, Sciahbasi, A., additional, Lioy, E., additional, Trani, C., additional, Burzotta, F., additional, Porto, I., additional, Rebuzzi, A. G., additional, Trusinskis, K., additional, Juhnevica, D., additional, Strenge, K., additional, Sondore, D., additional, Kumsars, I., additional, Jegere, S., additional, Narbute, I., additional, Grave, A., additional, Zakke, I., additional, Erglis, A., additional, Ferrari, C., additional, Bartorelli, A. L., additional, Saeed, M., additional, Cozma, D., additional, Pescariu, S., additional, Dragulescu, S. I., additional, Kamal, H. S., additional, Abdelfattah, A., additional, Abdelbary, A. M., additional, Elassar, H., additional, Naggar, A., additional, Khaled, M., additional, Fareed, A. M., additional, Pernes, J. M., additional, Gaux, J. C., additional, Prull, M. W., additional, Sasko, B., additional, Wirdemann, H., additional, Bittlinsky, A., additional, Butz, T., additional, Trappe, H. J., additional, Perazzolo Marra, M., additional, Cacciavillani, L., additional, Marzari, A., additional, De Lazzari, M., additional, Turri, R., additional, China, P., additional, Corbetti, F., additional, Iliceto, S., additional, Stazhadze, L. L., additional, Spiridonova, E. A., additional, Bulanova, N. A., additional, Ermolaev, A. A., additional, Savic, L., additional, Mrdovic, I., additional, Krljanac, G., additional, Perunicic, J., additional, Asanin, M., additional, Lasica, R., additional, Matic, M., additional, Vasiljevic, Z., additional, Ostojic, M., additional, Tichy, M., additional, Andrys, C., additional, Conti, A., additional, Poggioni, C., additional, Viviani, G., additional, Bulletti, F., additional, Boni, V., additional, Luzzi, M., additional, Vicidomini, S., additional, Donati, M., additional, Del Taglia, B., additional, Pini, R., additional, Sousa, O., additional, Fontes-Carvalho, R., additional, Caeiro, D., additional, Dias Ferreira, N., additional, Silva, G., additional, Pereira, E., additional, Ribeiro, J., additional, Albuquerque, A., additional, Gama Ribeiro, V., additional, Murai, M., additional, Takeda, Y., additional, Shinmyo, T., additional, Tanigawa, J., additional, Hazui, H., additional, Nakakohji, T., additional, Ohishi, Y., additional, Hoshiga, M., additional, Ishihara, T., additional, Hanafusa, T., additional, Belohlavek, J., additional, Rohn, V., additional, Kunstyr, J., additional, Lips, M., additional, Semrad, M., additional, Mlejnsky, F., additional, Tosovsky, J., additional, Linhart, A., additional, Lindner, J., additional, Sablik, Z., additional, Samborska-Sablik, A., additional, Drozdz, J., additional, Gaszynski, W., additional, Izquierdo-Gomez, M. M., additional, Juarez-Prera, R., additional, Blanco-Palacios, G., additional, Lakhdar, R., additional, Drissa, M., additional, Jedaida, B., additional, Drissa, H., additional, Sampaio, F., additional, Hsin, H.- T., additional, Huang, J.- H., additional, Chiu, K.- M., additional, Chen, Z.- S., additional, Lin, P.- C., additional, Chen, L.- Y., additional, Chu, S.- H., additional, Efthimiadis, I., additional, Skendros, P., additional, Sarantopoulos, A., additional, Boura, P., additional, Van Der Laan, A. M., additional, Van Der Vleuten, P. A., additional, Klees, M., additional, Tijssen, J. G. P., additional, Backus, B. E., additional, Six, A. J., additional, Kelder, J. H., additional, Mosterd, A., additional, Mast, E. G., additional, Mast, T. P., additional, Braam, R., additional, Tio, R., additional, Veldkamp, R., additional, Doevendans, P. A., additional, Paarup Dridi, N., additional, Holmvang, L., additional, Engstroem, T., additional, Rekik, S., additional, Brunet, J., additional, Hager, F. X., additional, Bayet, G., additional, Meille, L., additional, Quatre, J. M., additional, Sainsous, J., additional, Chu, P.- H., additional, Tang, C.- H., additional, Pogosova, N., additional, Koltunov, I. E., additional, Sapunova, I. D., additional, Vigodin, V. A., additional, Uhliar, R., additional, Schmidt, A., additional, Brockmeyer, B., additional, Suzuki, A., additional, Eki, Y., additional, Higuchi, H., additional, Yukawa, A., additional, Yamauchi, R., additional, Sato, Y., additional, Endo, Y., additional, Salazar Mendigucha Garcia, J., additional, Homs Vila, S., additional, Cequier Fillat, A., additional, Andion Ogando, R., additional, Sandin Fuentes, M., additional, Vegas Valle, J. M., additional, Gonzalez Garcia, I. A., additional, Duro Aguado, I. A., additional, Palomino Doza, A. J., additional, Gomez Salvador, I., additional, San Roman Calvar, J. A., additional, Mamarasulov, T. M., additional, Todorovic, L., additional, Cherneva, Z. C. H., additional, Denchev, S. D., additional, Heltai, K., additional, Boytsov, A., additional, Nikulina, N. N., additional, Zanna, D., additional, Marangelli, V., additional, Caiati, C., additional, Picon Heras, R., additional, Loureiro, M. J., additional, Urazovskaya, I., additional, Vinogradova, D., additional, Vasilieva, E., additional, Shpektor, A., additional, Conti, E., additional, Musumeci, M. B., additional, Lauri, F. M., additional, Dito, E., additional, De Giusti, M., additional, Lallo, A., additional, Fusco, D., additional, Davoli, M., additional, Volpe, M., additional, Autore, C., additional, Gamra, H., additional, Dridi, Z., additional, Hassine, M., additional, Addad, F., additional, Gherissi, I., additional, Reda, A., additional, Mahjoub, M., additional, Bouraoui, S., additional, Abdennadher, M., additional, Betbout, F., additional, Mota, P. M. F. P., additional, Silva, J. D., additional, Jankovic Tomasevic, R., additional, Djordjevic, V., additional, Djordjevic Radojkovic, D., additional, Scafa Udriste, A., additional, Fruntelata, A., additional, Gainoiu, E., additional, Bogdan, S., additional, Zamfir, D., additional, Teodorescu, C., additional, Guran, M., additional, Constantinescu, D., additional, Konopka, A., additional, Banaszewski, M., additional, Wojtkowska, I., additional, Stepinska, J., additional, Vidergold, J. V., additional, Osipova, I. V., additional, Tavrovskaya, T. V., additional, Galkina, J. V., additional, Timofeev, A. V., additional, Vorobyov, R. I., additional, Vorobyova, E. N., additional, Matos, L., additional, Carvalho, A. C. C., additional, Oliveira, W., additional, Cintra, F., additional, Poyares, D., additional, Andersen, M., additional, Martins, R., additional, Tufik, S., additional, Ostadal, P., additional, Brada, J., additional, Horakova, S., additional, Mlcek, M., additional, Hrachovina, V., additional, Kittnar, O., additional, Gorudko, I. V., additional, Buko, I. V., additional, Cherenkevich, S. N., additional, Polonetsky, L. Z., additional, Plotkin, V. Y., additional, Timoshina, M. A., additional, Azanchevskaya, S. V., additional, Chromov-Borisov, N. N., additional, Vorlat, A., additional, Snoep, L., additional, Claeys, M. J., additional, Vrints, C. J., additional, Palazzuoli, A., additional, Caputo, M., additional, Quatrini, I., additional, Calabro, A., additional, Antonelli, G., additional, Campagna, M. S., additional, Franci, B., additional, Nuti, R., additional, Maisel, A., additional, Negrini, M., additional, Minora, T., additional, Marino, P., additional, Seregni, R., additional, Tavlueva, E., additional, Barbarash, O., additional, Barbarash, L., additional, Janota, T., additional, Kudlicka, J., additional, Malik, K., additional, Wichterle, D., additional, Hradec, J., additional, Body, R., additional, Carley, S. D., additional, Mcdowell, G., additional, Nuttall, M., additional, Wibberley, C., additional, France, M., additional, Cruickshank, J. K., additional, Mackway-Jones, K., additional, Leon, M., additional, Cozma, C., additional, Mitu, F., additional, Almeida, D. R., additional, Dias, C. B., additional, Burazor, I., additional, Burazor, M., additional, Krstic, M., additional, Lazovic, M., additional, Vukmanovic, M., additional, Djordjevic, J., additional, Radovanovic, Z., additional, Ilic, D., additional, Bosnjakovic, P., additional, Ferreira, A. C., additional, Mateus, P. S., additional, Fontes, P., additional, Teixeira, T., additional, Conte, G., additional, Menozzi, A., additional, Solinas, E., additional, Bolognesi, M. G., additional, Tadonio, I., additional, Mantovani, F., additional, Cattabiani, A., additional, Vignali, L., additional, Ardissino, D., additional, Tautu, O., additional, Alexandrescu, A., additional, Niculescu, R., additional, Jankovic, R., additional, Bozinovic, N., additional, Santos, C., additional, Costa, F., additional, Cardoso, G., additional, Correia, I., additional, Fountoulaki, K., additional, Kastellanos, S., additional, Voltirakis, E., additional, Kokotos, A., additional, Michalakeas, C., additional, Kontsas, K., additional, Hasioti, K., additional, Iliodromitis, E. T., additional, Sandin Fuentes, M. G., additional, Zatarain Nicolas, E., additional, Martinez Uruena, N., additional, Alvarado Montes De Oca, M., additional, Dytrych, V., additional, Kovarnik, T., additional, Smid, O., additional, Kral, A., additional, Aroutunov, A. G., additional, Intwala, S., additional, Jegere, I., additional, Shaalan, H. S. H., additional, Pagava, Z., additional, Agladze, R., additional, Shakarishvili, R., additional, Sharashidze, N., additional, Gujejiani, L., additional, Saatashvili, G., additional, Katova, T. Z., additional, Kostova, V., additional, Simova, Y., additional, Vukotic, S., additional, Rafajlovski, S., additional, Romanovic, R., additional, Antonijevic, N., additional, Gligic, B., additional, Hutyra, M., additional, Skala, T., additional, Horak, D., additional, Vindis, D., additional, Taborsky, M., additional, Contine, A., additional, Del Pinto, M., additional, Angeli, F., additional, Verdecchia, P., additional, Borgognoni, F., additional, Grikstaite, E., additional, Pantano, P., additional, Ambrosio, G., additional, Cavallini, C., additional, Bonanad, C., additional, Sanchis, J., additional, Bodi, V., additional, Nunez, J., additional, Bosch, X., additional, Heras, M., additional, Pellicer, M., additional, Llacer, A., additional, Adao, L., additional, Oliveira, M., additional, Goncalves, H., additional, Primo, J., additional, Gama, V., additional, Lombardi, C., additional, Metra, M., additional, Bugatti, S., additional, Pasotti, E., additional, Quinzani, F., additional, Adamo, M., additional, Villa, C., additional, Rovetta, R., additional, Manerba, A., additional, Mariani, M., additional, Dushpanova, A., additional, Baroni, M., additional, Cerone, E., additional, Nardelli, A., additional, Gianetti, J., additional, Berti, S., additional, Feliciano, F., additional, Soares, R., additional, Santos, S., additional, Kruger, A., additional, Vondrakova, D., additional, Herget, J., additional, Navarro, C., additional, Cromie, N. A., additional, Adgey, J. A. A., additional, Caeiro Pereira, D., additional, Braga, P., additional, Fontes Carvalho, R., additional, Rodrigues, A., additional, Goncalves, M., additional, Simoes, L., additional, and Borisov, K. V., additional

Published
2010
Full Text
View/download PDF

19. O-0007 - Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study

Author

Cremolini, C., Loupakis, F., Lonardi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., Tonini, G., Valsuani, C., Chiara, S., Boni, C., Marcucci, L., Negri, F.V., Barone, C., Vitello, S., D'Amico, M., Granetto, C., Antoniotti, C., Salvatore, L., Fontanini, G., Tomcikova, D., Boni, L., and Falcone, A.

Published
2014
Full Text
View/download PDF

20. Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO

Author

Antoniotti, C., Cremolini, C., Loupakis, F., Francesca Bergamo, Grande, R., Tonini, G., Silvio, K. Garattini, Masi, G., Battaglin, F., Lucchesi, S., Salvatore, L., Corsi, D., Di Fabio, F., Banzi, M., Moretto, R., Sensi, E., Rossini, D., Tomcikova, D., Fontanini, G., Zagonel, V., Boni, L., and Falcone, A.

21. Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study

Author

Marmorino, F., Cremolini, C., Loupakis, F., Antoniotti, C., Barbara, C., Dargenio, F., Miraglio, E., Masi, G., Salvatore, L., Marta Schirripa, Borelli, B., Marcucci, L., Antonuzzo, L., Chiara, S., Banzi, C., Amoroso, D., Bonetti, A., Martignetti, A., Paris, M., Boni, L., Tomcikova, D., and Falcone, A.

22. ACE gene insertion/deletion polymorphism has a mild influence on the acute development of left ventricular dysfunction in patients with ST elevation myocardial infarction treated with primary PCI

Author

Toman Ondrej, Tomcikova Daniela, Kubkova Lenka, Prymusova Krystyna, Manousek Jan, Poloczek Martin, Jarkovsky Jiri, Kala Petr, Goldbergova Monika, Parenica Jiri, Tesak Martin, Tomandl Josef, Vasku Anna, and Spinar Jindrich

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background We evaluated the associations among angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism, ACE activity and post-myocardial infarction (MI) left ventricular dysfunction and acute heart failure (AHF) early after presentation with MI with ST-segment elevation (STEMI). Methods A total of 556 patients with STEMI treated by primary PCI (421 patients without AHF and 135 patients with AHF) were the study population. The activity of BNP, NT-ProBNP and ACE were measured at hospital admission and 24 h after MI onset. Left ventricular angiography was done before PCI; echocardiography was undertaken between the third and fifth day after MI. Results In comparison with the II genotypes group, the DD/ID group had a higher level of ACE activity upon hospital admission (p < 0.001). We found a significantly higher level of ACE activity in patients with moderate LV dysfunction (EF 40-54%) in comparison both with patients with preserved LV function (EF ≥55%) and with patients with severe LV dysfunction (p = 0.028). A non-significant trend towards a higher incidence of mild AHF (22.1% vs. 16.02%, p = 0,093), a significantly higher value of end-systolic volume (ESV/BSA) (30.0 ± 12.3 vs. 28.5 ± 13.0; p < 0.05) and lower EF (50.2 ± 11.1 vs. 52.7 ± 11.7; p < 0.05) in the DD/ID genotypes group was noted. Even after multiple adjustments according to multivariate models, the EF for the DD/ID group remained significantly lower (p = 0,033). The DD/ID genotypes were associated with a significantly higher risk of EF Conclusions These results suggest that the I/D polymorphism of ACE is associated with the development of LV dysfunction in the acute phase after STEMI. We demonstrated for the first time an association of the low ACE activity with the severe LV dysfunction, although patients with moderate LV dysfunction had higher level ACE activity than patients with preserved LV function.

Published
2010
Full Text
View/download PDF

23. Analysis of biometric parameters of 2340 eyes measured with optical biometer Lenstar LS900 in a Caucasian population.

Author

Popov I, Waczulikova I, Stefanickova J, Valaskova J, Tomcikova D, Shiwani HA, Delev D, Rodrigo L, Saxena S, Kruzliak P, and Krasnik V

Subjects
Aged, Anterior Chamber, Axial Length, Eye, Biometry, Cornea, Female, Humans, Male, Retrospective Studies, Tomography, Optical Coherence, Cataract diagnosis, Lens, Crystalline
Abstract

Objectives: To describe the pattern and mutual relationships between basic biometric characteristics of the eye in a Central European Caucasian population., Methods: A single-centre retrospective study of 2340 patients (965 males, 1375 females) scheduled for cataract surgery between 2014 and 2016. Measurements using laser interferometry included AL (axial length), K (average corneal curvature), ACD (anterior chamber depth), LT (lens thickness), CCT (central corneal thickness), AST (astigmatism) and WTW (white to white). Subjects were stratified by gender and controlled for age. Descriptive, correlation and regression analyses were performed on the data., Results: The mean AL was 23.33 ± 1.01 mm - higher in males (23.59 ± 0.99 mm), in comparison to females (23.15 ± 0.99 mm). The elderly had lower ACD and higher LT, while males had higher AL independent of age. Furthermore, LT and K decreased with AL, while ACD decreased with LT and increased with AL independent of age and gender., Conclusions: The estimates of the biometrics are obtained on a large sample of subjects and can serve as normative values for Lenstar LS900 in the Central European Caucasian population.

Published
2022
Full Text
View/download PDF

24. The Natural History of Retinal Vascular Changes from Infancy to Adulthood in Wyburn-Mason Syndrome.

Author

Horkovicova K, Popov I, Tomcikova D, Popova V, and Krasnik V

Subjects
Adult, Female, Fluorescein Angiography, Humans, Infant, Arteriovenous Fistula diagnostic imaging, Intracranial Arteriovenous Malformations diagnostic imaging, Neurocutaneous Syndromes diagnostic imaging, Retinal Artery diagnostic imaging
Abstract

Wyburn-Mason syndrome is a rare, non-hereditary congenital neurocutaneous disorder leading to arteriovenous malformations. Malformations are characterized by an artery that is directly connected to veins without a capillary system and forms a fragile mass of abnormal vessels. It can be found in the midbrain, in the eyes, orbit, and rarely in cutaneous nevi. Neurological and ocular symptoms are the most common. Ocular signs and symptoms include abnormally dilatated vessels of conjunctiva, nystagmus, strabismus, vitreous hemorrhage, vein occlusions, retinal detachment, etc. Neurological symptoms may include headaches, paralysis, epistaxis, hydrocephalus, and hemiparesis. Imaging modalities such as MRI/CT angiography, optical coherence angiography, and fluorescein angiography are the most important for the identification of arteriovenous malformations. In our case report, we present an eight-month-old girl with an incidental finding of retinal angiomatosis on the left eye and was subsequently diagnosed with Wyburn-Mason syndrome. We compare the findings from the first visit to her clinical findings 20 years later.

Published
2020
Full Text
View/download PDF

25. Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts.

Author

Silano V, Barat Baviera JM, Bolognesi C, Brüschweiler BJ, Chesson A, Cocconcelli PS, Crebelli R, Gott DM, Grob K, Lampi E, Riviere G, Steffensen IL, Tlustos C, Van Loveren H, Vernis L, Zorn H, Bolton D, Bover-Cid S, de Knecht J, Peixe L, Skandamis P, Baù A, Martino C, Messens W, Sarno E, Tomcikova D, and Mortensen A

Abstract

Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre-chill and pork meat cuts post-chill were assessed. Lactic acid treatments consisted of 2-5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2-4% solutions at temperatures of up to 40°C applied on carcasses by spraying or on cuts by spraying or dipping. The maximum treatment duration was 30 s. The Panel concluded that: [1] the treatments are of no safety concern, provided that the substances comply with the European Union specifications for food additives; [2] spraying of pork carcasses pre-chill with lactic acid was efficacious compared to untreated control, but based on the available data, the Panel could not conclude whether lactic acid was more efficacious than water treatment when spraying of pork carcasses pre-chill or pork meat cuts post-chill. The Panel concluded that dipping of pork meat cuts post-chill in lactic acid was more efficacious than water treatment. However, it could not conclude on the efficacy of acetic acid treatment of pork carcasses pre-chill and/or pork meat cuts post-chill; [3] the potential selection and emergence of bacteria with reduced susceptibility to biocides and/or resistance to therapeutic antimicrobials linked to the use of the substances is unlikely as long as Good Hygienic Practices are implemented; and [4] the release of both organic acids is not of concern for the environment, assuming that wastewaters released by the slaughterhouses are treated, if necessary, to counter the potentially low pH caused by lactic or acetic acid, in compliance with local rules., (© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.)

Published
2018
Full Text
View/download PDF

26. Update of the tolerable upper intake level for vitamin D for infants.

Author

Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjödin A, Stern M, Tomé D, Loveren HV, Vinceti M, Willatts P, Fewtrell M, Lamberg-Allardt C, Przyrembel H, Arcella D, Dumas C, Fabiani L, Martino L, Tomcikova D, and Neuhäuser-Berthold M

Abstract

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to revise the tolerable upper intake level (UL) for vitamin D for infants (≤ 1 year) set in 2012. From its literature review, the Panel concluded that the available evidence on daily vitamin D intake and the risk of adverse health outcomes (hypercalciuria, hypercalcaemia, nephrocalcinosis and abnormal growth patterns) cannot be used alone for deriving the UL for infants. The Panel conducted a meta-regression analysis of collected data, to derive a dose-response relationship between daily supplemental intake of vitamin D and mean achieved serum 25(OH)D concentrations. Considering that a serum 25(OH)D concentration of 200 nmol/L or below is unlikely to pose a risk of adverse health outcomes in infants, the Panel estimated the percentage of infants reaching a concentration above this value at different intakes of vitamin D. Based on the overall evidence, the Panel kept the UL of 25 μg/day for infants aged up to 6 months and set a UL of 35 μg/day for infants 6-12 months. The Panel was also asked to advise on the safety of the consumption of infant formulae with an increased maximum vitamin D content of 3 μg/100 kcal (Commission Delegated Regulation (EU) 2016/127 repealing Directive 2006/141/EC in 2020). For infants aged up to 4 months, the intake assessment showed that the use of infant formulae containing vitamin D at 3 μg/100 kcal may lead some infants to receive an intake above the UL of 25 μg/day from formulae alone without considering vitamin D supplemental intake. For infants aged 4-12 months, the 95th percentile of vitamin D intake (high consumers) estimated from formulae and foods fortified or not with vitamin D does not exceed the ULs, without considering vitamin D supplemental intake., (© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.)

Published
2018
Full Text
View/download PDF

27. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.

Author

Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, Stellato M, Marmorino F, Schirripa M, Urbano F, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Fea E, Di Donato S, Chiara S, Tonini G, Tomcikova D, Boni L, Falcone A, and Santini D

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bevacizumab administration & dosage, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Colorectal Neoplasms drug therapy, Colorectal Neoplasms pathology, Female, Fluorouracil administration & dosage, Humans, Leucovorin administration & dosage, Male, Middle Aged, Organoplatinum Compounds administration & dosage, Prognosis, Retrospective Studies, Colorectal Neoplasms blood, Lymphocyte Count, Neoplasm Metastasis, Neutrophils cytology
Abstract

Background: Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial., Patients and Methods: Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR < 3) versus high (NLR ≥ 3) NLR, as primary analysis. As secondary analysis, NLR was treated as an ordinal variable with three levels based on terciles distribution., Results: NLR at baseline was available for 413 patients. After multiple imputation at univariate analysis, patients with high NLR had significantly shorter progression-free survival (PFS) [hazard ratio (HR) 1.27 (95% CI 1.05-1.55), P = 0.017] and overall survival (OS) [HR 1.56 (95% CI 1.25-1.95), P < 0.001] than patients with low NLR. In the multivariable model, NLR retained a significant association with OS [HR 1.44 (95% CI 1.14-1.82), P = 0.014] but not with PFS [HR 1.18 (95% CI 0.95-1.46), P = 0.375]. No interaction effect between treatment arm and NLR was evident in terms of PFS (P for interaction = 0.536) or OS (P for interaction = 0.831). Patients with low [HR 0.84 (95% CI 0.64-1.08)] and high [HR 0.73 (95% CI 0.54-0.97)] NLR achieved similar PFS benefit from the triplet and consistent results were obtained in terms of OS [HR 0.83 (95% CI 0.62-1.12) for low NLR; HR 0.82 (95% CI 0.59-1.12) for high NLR]., Conclusion: This study confirmed the prognostic role of NLR in mCRC pts treated with bevacizumab plus chemotherapy in the first line, showing the worse prognosis of pts with high NLR. The advantage of the triplet is independent of NLR at baseline.

Published
2018
Full Text
View/download PDF

28. Why is it necessary to examine retina when the patient suffers from aplastic anemia?

Author

Tomcikova D, Gerinec A, Busanyova B, Gresikova M, Biskup S, and Hortnagel K

Subjects
Child, Preschool, Humans, Laser Coagulation, Male, Retina pathology, Visual Acuity, Anemia, Aplastic complications, Bone Diseases, Metabolic complications, Retinal Diseases diagnosis, Retinal Diseases etiology
Abstract

Purposes: To inform about a case of Revesz syndrome (RS) with initial ophthalmological symptomatology of severe proliferative vitreoretinopathy of the left eye (LE). After the aplastic anemia had developed, RS was established. The exudative retinopathy was successfully treated with photocoagulation on the right eye (RE)., Background: RS is characterized by fatal bone marrow failure, exudative retinopathy, neuroradiographic abnormalities, neurodevelopmental delay and skin abnormalities. Non-treated exudative retinopathy leads to blindness., Methods: We report ophthalmological findings as follows: fundus photography and fluorescein angiography (FA) acquired by examinations under general anesthesia in patient with RS. Results of genetic tests helped to establish the diagnosis., Results: Two‑year old Caucasian male was examined due to total retinal detachment on LE and signs of chorioretinal scarring on RE. In preoperative screening, thrombocytopenia was detected; later, severe pancytopenia developed. Considering the hematological findings and clinical appearance, we suspected RS, which was confirmed by genetic tests. We found a pathogenic mutation in gene TINF2 (variant c.865C>T;p.Pro289Ser) in a mosaic state with autosomal dominant mode of inheritance. This mutation has not been described in RS yet. Blind LE was enucleated because of dolorous neovascular glaucoma. FA of RE shows excessive areas of capillary nonperfusion with vascular abnormalities and exudation. After the photocoagulation, the visual acuity (VA) on RE remains 0.9 at the age of 7 years., Conclusions: RS is an extremely rare condition.  The initial symptomatology could be ophthalmological or hematological. The positive finding of TINF2 gene mutation helped in establishing the correct diagnosis. The ischemic retinopathy was successfully treated by photocoagulation (Fig. 6, Ref. 6). Text in PDF www.elis.sk.

Published
2018
Full Text
View/download PDF

29. Incomprehensible treatment of retinoblastoma with high doses of vitamin C.

Author

Tomcikova D, Gerinec A, Busanyova B, Husakova K, Kuniak M, and Autrata R

Subjects
Combined Modality Therapy, Female, Humans, Infant, Magnetic Resonance Imaging, Male, Orbital Neoplasms diagnostic imaging, Retinal Neoplasms diagnostic imaging, Retinal Neoplasms surgery, Retinoblastoma diagnostic imaging, Retinoblastoma surgery, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Ascorbic Acid administration & dosage, Orbit Evisceration, Orbital Neoplasms therapy, Retinal Neoplasms therapy, Retinoblastoma therapy
Abstract

Purposes: To inform about a case of neglected retinoblastoma that was left untreated for more than 3 years by parents. During this time period the local finding worsened from endophytic retinoblastoma group B according IIRC (ABC classification) to extraorbital propagation., Background: Retinoblastoma is the most common intraocular tumor in childhood, that occurs approximately in 1 : 15-20 000 births worldwide. In European region cases of extraocular propagation are very infrequent. Extraorbital propagation is extremely rare in middle and high income countries., Methods: We report the preoperative ophthalmological findings, MRI imaging, treatment methods and postoperative results of this case., Results: After initial dose of six courses of chemotherapy patient underwent surgery (orbital exenteration). In postoperative period patient received two more courses of chemotherapy. In spite of progressed stage of the disease, we obtained good results with our therapy., Conclusions: We suppose that good treatment results, in spite of extraordinary long lag interval and hopeless pretreatment condition, caused by alternative therapy with high doses vitamin C and no protein intake, were caused by therapeutic naïve retinoblastoma with an absence of RB1 gene mutation (Fig. 6, Ref. 7).

Published
2018
Full Text
View/download PDF

30. Cataract and early nystagmus due to galactokinase deficiency.

Author

Bzduch V, Tomcikova D, Gerinec A, and Behulova D

Subjects
Cataract complications, Cataract etiology, Diagnostic Techniques, Ophthalmological, Humans, Infant, Male, Mutation, Cataract congenital, Galactose deficiency, Galactosemias complications, Galactosemias etiology, Nystagmus, Pathologic complications, Nystagmus, Pathologic etiology
Published
2017
Full Text
View/download PDF

31. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.

Author

Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G, Loupakis F, Borelli B, Chiara S, Banzi MC, Miraglio E, Amoroso D, Dargenio F, Bonetti A, Martignetti A, Paris M, Tomcikova D, Boni L, Falcone A, and Cremolini C

Subjects
Adenocarcinoma pathology, Adult, Aged, Biomarkers, Tumor blood, Chemotherapy, Adjuvant, Colorectal Neoplasms pathology, Disease Progression, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Prognosis, Treatment Outcome, Adenocarcinoma drug therapy, Angiogenesis Inhibitors therapeutic use, Bevacizumab therapeutic use, Colorectal Neoplasms drug therapy, L-Lactate Dehydrogenase blood
Abstract

Background: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified., Methods: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy. A subgroup analysis according to baseline serum lactate dehydrogenase (LDH) levels was carried out., Results: A significant interaction effect between LDH levels and treatment was found in terms of progression-free survival (PFS; P=0.002). Although patients with low LDH levels achieved significant PFS benefit from the continuation of bevacizumab (HR: 0.39 (95% CI: 0.23-0.65)), patients with high levels did not (HR: 1.10 (95% CI: 0.74-1.64)). Consistent results were reported in overall survival (OS; P=0.075)., Conclusions: As preclinical evidence suggests that serum LDH may be a marker of tumour angiogenesis activation, low levels may indicate that bevacizumab is still efficacious in inhibiting angiogenesis. Validation of present results in subgroup analyses of other randomised trials of second-line angiogenesis inhibitors is warranted., Competing Interests: LA reports serving on advisory board or having consultant role for Roche, Amgen, Eli-Lilly, Bayer, Novartis, Ipsen; FL reports serving on advisory board for Amgen and Sanofi-Aventis, receiving lecture fees from Sanofi-Aventis, Bayer, Roche and grant support from Roche and Merck Serono; AF reports serving on advisory board for Amgen, Bayer, Merck Serono, Roche and Sanofi-Aventis, receiving lecture fees from Merck Serono, Roche, Amgen, Bayer, Amgen, Bayer, Merck Serono, Roche and Sanofi-Aventis and grant support from Amgen, Merck Serono and Roche; CC reports serving on advisory board for Roche, Bayer, Amgen and Merck Serono and receiving lecture fees from Sanofi-Aventis and Bayer. All remaining authors declared no conflicts of interest.

Published
2017
Full Text
View/download PDF

32. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Author

Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, and Marra F

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Chi-Square Distribution, Female, Humans, Kaplan-Meier Estimate, Liver Cirrhosis mortality, Liver Neoplasms etiology, Liver Neoplasms mortality, Liver Neoplasms pathology, Logistic Models, Magnetic Resonance Imaging, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Niacinamide adverse effects, Niacinamide therapeutic use, Phenylurea Compounds adverse effects, Proportional Hazards Models, Protein Kinase Inhibitors adverse effects, Risk Factors, Sorafenib, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Hepatocellular drug therapy, Liver Cirrhosis complications, Liver Neoplasms drug therapy, Niacinamide analogs & derivatives, Phenylurea Compounds therapeutic use, Protein Kinase Inhibitors therapeutic use
Abstract

Aim: To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma (HCC) in patients with established cirrhosis., Methods: From October 2009 to July 2012 patients with an established diagnosis of cirrhosis and HCC treated with sorafenib were consecutively enrolled. According to the Barcelona Clinic Liver Cancer (BCLC) classification, patients were in the advanced stage (BCLC-C) or in the intermediate stage (BCLC-B) but unfit or unresponsive to other therapeutic strategies. Treatment was evaluated performing a 4-phase computed tomography or magnetic resonance imaging scan every 2-3 mo, and analyzed according to the modified Response Evaluation Criteria in Solid Tumors. Sorafenib was administered at 800 mg/d, until radiological progression or occurrence of unacceptable adverse events (AEs). Univariate and multivariate analyses identified predictors of 16-wk clinical benefit and overall survival., Results: Forty-four patients were enrolled, 15 had intermediate HCC and 14 a Child-Pugh score of B7. AEs caused treatment interruption in 19 patients (43%), and median treatment duration was shorter in this subset (5 wk vs 19 wk, P < 0.001) and in the BCLC-C subgroup (13 wk vs 40 wk, P = 0.015). No significant differences in the reason for treatment interruption or in treatment duration were found comparing patients in Child-Pugh class A vs B or in patients older or younger than 70 years. After 16 wk of treatment, 18 patients (41%) had stable disease or partial response. Patients with viral infection or BCLC-C were at higher risk of disease progression. ECOG, extrahepatic spread, macrovascular invasion, alpha-fetoprotein or alkaline phosphatase levels at admission were independent predictors of overall survival., Conclusion: In patients with cirrhosis and HCC treated with sorafenib, AEs are a common cause of early treatment withdrawal. Vascular invasion and extrahepatic spread condition early response to treatment and survival. Baseline biochemical parameters may be helpful to identify patients at higher risk of shorter overall survival.

Published
2014
Full Text
View/download PDF

33. Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: classification tree analysis on data from the Acute Heart Failure Database-Main registry.

Author

Tomcikova D, Felsoci M, Spinar J, Miklik R, Mikusova T, Vitovec J, Spinarova L, Widimsky P, Linhart A, Belohlavek J, Fedorco M, Cihalik C, Malek F, Bambuch M, Vaclavik J, Kettner J, Jarkovsky J, Dusek L, and Parenica J

Subjects
Aged, Aged, 80 and over, Female, Heart Failure classification, Humans, Male, Middle Aged, Registries, Risk Factors, Heart Failure mortality, Hospital Mortality, Models, Statistical, Risk Assessment methods
Abstract

Purpose: The purposes of this study are to identify the strongest clinical parameters in relation to in-hospital mortality, which are available in the earliest phase of the hospitalization of patients, and to create an easy tool for the early identification of patients at risk., Materials and Methods: The classification and regression tree analysis was applied to data from the Acute Heart Failure Database-Main registry comprising patients admitted to specialized cardiology centers with all syndromes of acute heart failure. The classification model was built on derivation cohort (n = 2543) and evaluated on validation cohort (n = 1387)., Results: The classification tree stratifies patients according to the presence of cardiogenic shock (CS), the level of creatinine, and the systolic blood pressure (SBP) at admission into the 5 risk groups with in-hospital mortality ranging from 2.8% to 66.2%. Patients without CS and creatinine level of 155 μmol/L or less were classified into very-low-risk group; patients without CS, creatinine level greater than 155 μmol/L, and SBP greater than 103 mm Hg, into low-risk group, whereas patients without CS, creatinine level greater than 155 μmol/L, and SBP of 103 mm Hg or lower, into intermediate-risk group. The high-risk group patients had CS and creatinine of 140 μmol/L or less; patients with CS and creatinine level greater than 140 μmol/L belong to very-high-risk group. The area under receiver operating characteristic curve was 0.823 and 0.832, and the value of Brier's score was estimated on level 0.091 and 0.084, for the derivation and the validation cohort, respectively., Conclusions: The presented classification model effectively stratified patients with all syndromes of acute heart failure into in-hospital mortality risk groups and might be of advantage for clinical practice., (Copyright © 2013 Elsevier Inc. All rights reserved.)

Published
2013
Full Text
View/download PDF

34. ACE gene insertion/deletion polymorphism has a mild influence on the acute development of left ventricular dysfunction in patients with ST elevation myocardial infarction treated with primary PCI.

Author

Parenica J, Goldbergova MP, Kala P, Jarkovsky J, Poloczek M, Manousek J, Prymusova K, Kubkova L, Tomcikova D, Toman O, Tesak M, Tomandl J, Vasku A, and Spinar J

Subjects
Acute Disease, Angioplasty, Balloon, Coronary, Female, Humans, Male, Myocardial Infarction complications, Myocardial Infarction therapy, Peptidyl-Dipeptidase A physiology, Ventricular Dysfunction, Left etiology, Gene Deletion, Mutagenesis, Insertional, Peptidyl-Dipeptidase A genetics, Polymorphism, Genetic, Ventricular Dysfunction, Left genetics
Abstract

Background: We evaluated the associations among angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism, ACE activity and post-myocardial infarction (MI) left ventricular dysfunction and acute heart failure (AHF) early after presentation with MI with ST-segment elevation (STEMI)., Methods: A total of 556 patients with STEMI treated by primary PCI (421 patients without AHF and 135 patients with AHF) were the study population. The activity of BNP, NT-ProBNP and ACE were measured at hospital admission and 24 h after MI onset. Left ventricular angiography was done before PCI; echocardiography was undertaken between the third and fifth day after MI., Results: In comparison with the II genotypes group, the DD/ID group had a higher level of ACE activity upon hospital admission (p < 0.001). We found a significantly higher level of ACE activity in patients with moderate LV dysfunction (EF 40-54%) in comparison both with patients with preserved LV function (EF ≥ 55%) and with patients with severe LV dysfunction (p = 0.028). A non-significant trend towards a higher incidence of mild AHF (22.1% vs. 16.02%, p = 0,093), a significantly higher value of end-systolic volume (ESV/BSA) (30.0 ± 12.3 vs. 28.5 ± 13.0; p < 0.05) and lower EF (50.2 ± 11.1 vs. 52.7 ± 11.7; p < 0.05) in the DD/ID genotypes group was noted. Even after multiple adjustments according to multivariate models, the EF for the DD/ID group remained significantly lower (p = 0,033). The DD/ID genotypes were associated with a significantly higher risk of EF <45% (OR 2.04 [95% CI 1.28; 3.25])., Conclusions: These results suggest that the I/D polymorphism of ACE is associated with the development of LV dysfunction in the acute phase after STEMI. We demonstrated for the first time an association of the low ACE activity with the severe LV dysfunction, although patients with moderate LV dysfunction had higher level ACE activity than patients with preserved LV function.

Published
2010
Full Text
View/download PDF

35. Association between laboratory markers and presence of coronary artery disease.

Author

Kincl V, Panovsky R, Meluzin J, Semenka J, Groch L, Tomcikova D, Jarkovsky J, and Dusek L

Subjects
Aged, Blood Glucose analysis, C-Reactive Protein analysis, Cholesterol, HDL blood, Coronary Angiography, Coronary Artery Disease blood, Creatinine blood, Female, Fibrinogen analysis, Humans, Leukocyte Count, Male, Middle Aged, Triglycerides blood, Uric Acid blood, Biomarkers blood, Coronary Artery Disease diagnosis
Abstract

Unlabelled: The aim of this paper is to elucidate the relation between laboratory markers and coronary artery disease (CAD)., Methods: The study involved 1254 consecutive patients with suspected or known CAD referred for coronary angiography. The blood samples including blood cell count, C-reactive protein, fibrinogen, uric acid, creatinine, and lipid spectrum were obtained after overnight fasting. One hundred and thirty-three patients were excluded due to incomplete records or inacceptable laboratory values. Differences among groups were tested with one-way ANOVA and Bonferroni post-hoc test for continuous variables and with chi-square test for categorical variables. Univariate and multivariate logistic regression was adopted for the analysis of risk factors and development of models for classification of patients into clinical categories., Results: The linear logistic regression showed association of patient's biochemical markers with the presence of disease. Both acute and chronic CAD were associated with leukocyte count (Odds ratios 1.45 and 1.26), CRP (1.13; 1.05), fibrinogen (4.23; 1.95), uric acid (1.27; 1.38), creatinine (1.04; 1.04), HDL cholesterol (0.07; 0.12), triglycerides (1.4; 1.52) and glucose (1.56; 1.39). Presence of insignificant atherosclerosis was influenced only by fibrinogen (OR 1.73), creatinine (1.02), HDL cholesterol (0.5) and glucose level (1.23). There was no difference between one- and multivessel disease in laboratory values., Conclusion: Leukocyte count, CRP level, triglycerides and uric acid are associated with the presence of both acute and chronic ischaemic heart disease, but not with number of stenosed vessels. In addition, glycemia, HDL cholesterol and namely fibrinogen and creatinine have relation to occurence of insignificant atherosclerosis.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results